Global Information
회사소개 | 문의 | 위시리스트

암치료용 PARP 저해제 시장 : 가격, 투약용량, 임상 파이프라인 전망

Global PARP Inhibitors Cancer Therapy Market, Price, Dosage & Clinical Pipeline Outlook 2023

리서치사 KuicK Research
발행일 2018년 04월 상품 코드 628063
페이지 정보 영문 200 Pages
가격
US $ 2,200 ₩ 2,597,000 Unprintable PDF by E-mail (Single User License)
US $ 2,600 ₩ 3,070,000 CD-ROM
US $ 3,300 ₩ 3,896,000 Hard Copy
US $ 4,000 ₩ 4,723,000 Printable PDF by E-mail (Multi-User License)

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



암치료용 PARP 저해제 시장 : 가격, 투약용량, 임상 파이프라인 전망 Global PARP Inhibitors Cancer Therapy Market, Price, Dosage & Clinical Pipeline Outlook 2023
발행일 : 2018년 04월 페이지 정보 : 영문 200 Pages

세계의 PARP 저해제(PARP Inhibitors) 시장에 대해 조사했으며, 시장 현황, 동향, 역학, 시장에 영향을 미치는 최근 발전, 치료제 가격·매출·환자 1명당 치료 비용, 시장 예측 등의 정보를 정리하여 전해드립니다.

제1장 Poly(ADP-Ribose) 중합효소 억제제의 서론

  • 독특한 암치료제로서의 PARP 저해제
  • PARP 저해제의 발전적인 측면
  • PARP 단백질 & 저해제의 준비 단계

제2장 PARP 단백질 : 암치료제 개발에 있어서 매력적인 표적

  • PARP 저해제 표적 부위의 구조적 조직
  • PARP 저해제의 구조적 조직

제3장 정상세포 및 암세포에서 PARP 단백질의 역할에 대한 치료적 개발

  • 정상세포에서 PARP 단백질의 중요성
  • 종양 형성에서 PARP 단백질의 중요성 : 세포 분열 및 DNA 복구에 대한 영향
  • PARP 저해제 : 암세포를 제거하는 주목해야 할 작용기전

제4장 세계의 Poly(ADP-Ribose) 중합효소 억제제 임상 파이프라인 개요

제5장 암 단독요법으로서의 시판중인 Poly(ADP-Ribose) 중합효소 억제제(PARP 저해제)

  • Olaparib
  • Rucaparib
  • Niraparib
  • 임상 파이프라인의 유망한 PARP 저해제 : 유효성, 투약용량, 예상 가격

제6장 세계의 암치료용 PARP 저해제 : 시장 현황

  • PARP 저해제 시장 개요
  • 시장 세분화 : 특허
  • 시장 세분화 : 의약품 매출
  • 시장 동향

제7장 기존 암치료에 의한 PARP 저해제 : 유효성, 투약용량, 가격 분석

  • 화학요법과 PARP 저해제
  • 방사선 요법과 PARP 저해제

제8장 최신 암치료에 의한 PARP 저해제의 유효성 개선

  • PARP 저해제와 표적치료
  • 면역치료와 PARP 저해제

제9장 세계의 PARP 저해제 시장 성장 촉진요인

  • 몇 개 PARP 저해제의 연속 승인과 가까운 미래에 승인될 전망인 제품
  • 강력한 임상 파이프라인
  • 대규모의 환자 기반
  • 인가를 획득한 PARP 저해제의 상업적인 성공

제10장 세계 PARP 저해제 시장의 과제

  • 과학의 한계와 부작용 수
  • 복잡한 승인 프로세스

제11장 세계의 PARP 저해제 시장 예측

  • 파이프라인의 PARP 저해제

제12장 세계의 세계의 PARP 저해제 임상 파이프라인 : 기업, 적응증, 단계별

  • 전임상
  • 임상
  • Phase I
  • Phase I/II
  • Phase II
  • Phase III

제13장 출시된 암치료용 PARP 저해제 임상 고찰 : 기업별, 증상별

  • Olaparib(Lynparza)
  • Niraparib(Zejula)
  • Rucaparib(Rubraca)

제14장 경쟁 환경

  • 2X Oncology
  • Abott Laboratories
  • Cephalon
  • Checkpoint Therapeutics
  • Eisai Inc.
  • IMPACT Therapeutics
  • Jeil Pharmaceuticals
  • KuDOS Pharmaceuticals
  • Kyowa Hakko Kirin Co.
  • Lead Therapeutics
  • Shanghai De Novo Pharmatech
LSH 18.04.27

Report highlights:

  • Current Market Trends & Development Scenario
  • Drug Availability, Dosage & Treatment Schedule
  • Commercially Available Drugs Price Analysis
  • Global Cancer PARP Inhibitors Clinical Pipeline Overview: 31 Drugs
  • Clinical & Patent Insight on Commercially Available Drugs: 3 Drugs
  • Market Segmentation by Drug Patent & Deals

Conventional therapies like surgery, radiotherapy and chemotherapies are currently the dominant form of cancer treatment globally. However, majority of these methods have several limitations with multiple adverse effects which has led to the emergence of much more innovative approach, collectively known as targeted therapies. Targeted cancer therapy segment currently flourishes with several types of therapeutics among which PARP inhibitors have gained immense popularity due to their superior efficacy to conventional therapeutics.

Inhibitors include drugs or substances that block the growth and spread of cancer by interfering with specific molecular targets that are involved in the growth, progression, and spread of cancer. PARP inhibitors are recent entrants in the targeted therapy segment which have gained worldwide popularity as the most common type treatment in certain clinical indications like ovarian cancer and breast cancer.

Poly-ADP Ribose Polymerase or PARP are special proteins that play a key role in assisting damaged cells to repair themselves. The initial clinical testing of PARP inhibitors began nearly a decade ago, following the discovery that these agents in vitro had heightened anticancer activity in cancer cells that harbored BRCA mutations compared to BRCA wild-type cancer cells with intact DNA repair.

Research proved that fault in either of BRCA 1 and BRCA 2 genes have an increased risk of certain types of cancer such as breast cancer, ovarian cancer and prostate cancer. Cells are less likely to repair themselves if there is a fault in one or both of these genes. Blocking PARP with a PARP inhibitor showed impressive results in preventing the proliferation of cancer cells by interfering with their DNA repair mechanism and killing them, thus resulting in a therapeutic outcome.

Currently, there are 3 PARP inhibitors that have been approved for use in patients with suspected or confirmed BRCA-mutated advanced ovarian cancer that has been treated with 3 or more prior lines of chemotherapy. Olaparib (Lynpraza) was the first PARP inhibitor to receive approval in 2014 followed by Rucaparib in 2016 and Niraparib in 2017.

Trends show that the cancer therapy market is steadily shifting from conventional therapeutics to modern therapeutics due to their better safety, efficacy and specificity; thus creating an excellent opportunity for promising therapeutics like PARP inhibitors.

PARP inhibitors have proved to be a commercial success in the modern cancer therapeutic segment. For instance, Lynpraza(Olaparib), marketed by AstraZeneca reported global sales of over US$ 400 Million in 2017; making it one of the most profitable cancer therapy drugs of the year. Lynpraza sales have more than doubled since its approval which projects an optimistic growth in the future. Olaparib is followed by Niraparib with sales of over US$ 109 Million during first nine months of commercial launch. Rucaparib - the most recent PARP inhibitor to enter the market is estimated to generate revenue of over US$ 40 Million by the end of 2018.

The US currently dominates the global PARP inhibitors market leading both in marketing and research followed by Europe. Involvement of regions like South Korea, Japan and Middle East has led to better market penetration and overall better market growth.

The demand for PARP inhibitors has grown exponentially with the increasing incidence of cancer. Further, their enhanced efficacy in cancer treatment when combined with conventional therapeutics like chemotherapy and radiation therapy has led to an exponential growth in sales; which is further strengthened by a robust clinical pipeline under development. With several favorable factors paving the path for success, PARP inhibitors could be one of the leading cancer therapeutics of the future

KuicK Research Analysis of the global PARP inhibitors market provides an in-depth analysis of the current market scenario, trends, dynamics and recent advances that might have an impact on the PARP inhibitors market. Key data like pricing of drugs, sales and cost of therapy per patient have been used to draw an accurate analysis of the PARP inhibitors market. Finally, KuicK Research analysis of forecast and projections regarding the future of PARP Inhibitors market indicate an exciting opportunity waiting in this highly profitable segment of cancer therapy.

Table of Contents

1. Introduction to Poly (ADP-Ribose) Polymerase Inhibitors

  • 1.1 PARP Inhibitors as Unique Cancer Therapy
  • 1.2 Evolutionary Aspects of PARP Inhibitors
  • 1.3 Prelude to PARP Proteins & their Inhibitors

2. PARP Proteins: An Attractive Target for Developing Cancer Therapeutics

  • 2.1 Structural Organization of Target Site of PARP Inhibitors
  • 2.2 Structural Organization of PARP Inhibitors

3. Therapeutic Exploitation of Role of PARP Proteins in Normal Cells & Cancer Cells

  • 3.1 Significance of PARP Proteins in Normal Cells
  • 3.2 Significance of PARP Proteins in Tumorigenesis: Affecting Cell Division & DNA Repair
  • 3.3 PARP Inhibitors: Distinct Modes of Action for Eliminating Cancer Cells

4. Global Poly (ADP-Ribose) Polymerase Inhibitors Clinical Pipeline Overview

5. Commercially Available Poly (ADP-Ribose) Polymerase Inhibitors (PARP Inhibitors) as Cancer Monotherapy

  • 5.1 Olaparib
    • 5.1.1 Availability, Dosage & Treatment Schedule
    • 5.1.2 Price Analaysis
  • 5.2 Rucaparib
    • 5.2.1 Availability, Dosage & Treatment Schedule
    • 5.2.2 Price Analysis
  • 5.3 Niraparib
    • 5.3.1 Availability, Dosage & Treatment Schedule
    • 5.3.2 Price Analysis
  • 5.4 Promising PARP Inhibitors in Clinical Pipeline: Efficiency, Dosage & Expected Price
    • 5.4.1 Talazoparib
    • 5.4.2 Veliparib

6. Global PARP Inhibitor Cancer Therapy Current Market Scenario

  • 6.1 PARP Inhibitor Market Outline
  • 6.2 Market Segmentation by Patent
  • 6.3 Market Segmentation by Drug Sales
  • 6.4 Market Trends

7. PARP Inhibitors with Conventional Cancer Therapy: Efficacy, Dosage & Price Analysis

  • 7.1 PARP Inhibitors with Chemotherapy
    • 7.1.1 Temozolomide
    • 7.1.2 Platinum Salts
    • 7.1.3 Taxanes
    • 7.1.4 Gemcitabine
    • 7.1.5 Topoisomerase Inhibitors/Poisons
  • 7.2 PARP Inhibitors in Combination with Radiotherapy

8. Improved Efficacy of PARP Inhibitors by Modern Cancer Therapies

  • 8.1 Combination of PARP Inhibitors & Targeted Therapies
    • 8.1.1 PARP Inhibitors with EGFR Inhibitors
    • 8.1.2 PARP Inhibitors with VEGFR Inhibitors
    • 8.1.3 PARP Inhibitors with PI3K/mTOR Inhibitors
    • 8.1.4 PARP Inhibitors with Trastuzumab
    • 8.1.5 Anti-endocrine agents
    • 8.1.6 HSP90 Inhibitors
    • 8.1.7 IGF-1R & HDAC Inhibitors
  • 8.2 PARP Inhibitors in Combination with Immunotherapies

9. Factors Driving Global PARP Inhibitors Market

  • 9.1 Consecutive Approvals of Several PARP Inhibitors & Anticipated Approvals in the Nearby Future
  • 9.2 Strong clinical Pipeline
  • 9.3 Large Patient Base
  • 9.4 Commercial Success of Approved PARP Inhibitors

10. Global PARP Inhibitor Market Challenges

  • 10.1 Scientific Limitations and the Number of Side Effects
  • 10.2 Tedious approval process

11. Global PARP Inhibitors Market Future Forecast

  • 11.1 PARP Inhibitors in the Pipeline: Shaping the Future of Ineffectively Treated Cancer
    • 11.1.1 PARP Inhibitors for Prostate Cancer
    • 11.1.2 PARP Inhibitors for Lung Cancer
    • 11.1.3 PARP Inhibitors in Pancreatic Cancer
    • 11.2 Market Opportunity

12. Global Cancer PARP Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 12.1 Preclinical
  • 12.2 Clinical
  • 12.3 Phase-I
  • 12.4 Phase-I/II
  • 12.5 Phase-II
  • 12.6 Phase-III

13. Marketed Cancer PARP Inhibitors Clinical Insight by Company & Indication

  • 13.1 Olaparib (Lynparza)
  • 13.2 Niraparib (Zejula)
  • 13.3 Rucaparib (Rubraca)

14. Competitive Landscape

  • 14.1 2X Oncology
  • 14.2 Abott Laboratories
  • 14.3 Cephalon
  • 14.4 Checkpoint Therapeutics
  • 14.5 Eisai Co. Ltd
  • 14.6 IMPACT Therapeutics
  • 14.7 Jeil Pharmaceuticals
  • 14.8 KuDOS Pharmaceuticals
  • 14.9 Kyowa Hakko Kirin
  • 14.10 Lead Therapeutics
  • 14.11 Shanghai De Novo Pharmatech

List of Figures

  • Figure 1-1: History & Evolution of PARP Inhibitors
  • Figure 1-2: Biochemistry & Biological Functions Of Poly ADP-Ribosylation Reaction Mediated by Poly (ADP-Ribose) Polymerase (PARP) Enzymes
  • Figure 2-1: Structural Organization of PARP-1 & PARP-2 Enzymes
  • Figure 3-1: PARP Proteins in DNA Damage Repair Mechanism
  • Figure 3-2: Importance of PARP in DNA Repair Mechanism in Normal Cells
  • Figure 3-3: Dual Action of PARP inhibition for Cancer Treatment
  • Figure 4-1: Global - Cancer PARP Inhibitors Pipeline by Phase (%), 2018 till 2023
  • Figure 4-2: Global - Cancer PARP Inhibitors Pipeline by Phase (Number), 2018 till 2023
  • Figure 4-3: Global - Cancer PARP Inhibitors Pipeline by Phase (%),2018 till 2023
  • Figure 4-4: Global - Cancer PARP Inhibitors Pipeline by Phase (Number), 2018 till 2023
  • Figure 5-1: Progression Free Survival in Patients with Platinum-Sensitive, Relapsed, BRCA-mutant Ovarian Cancer by Using a PARP Inhibitor for 30 Months
  • Figure 5-2: Olaparib - Available Concentrations (mg), 2018
  • Figure 5-3: Olaparib - Dosage Analysis (mg/Day)
  • Figure 5-4: Olaparib - 150mg & 100mg Tablet Dosage Analysis (mg/12 hour) By Tablet Concentration
  • Figure 5-5: Olaparib - 50mg Tablet Dosage Analysis (Number of Capsules/Day)
  • Figure 5-6: Olaparib - Price Analysis by Type (US$/Unit), 2018
  • Figure 5-7: Olaparib - Price Analysis by Type (US$/Packet), 2018
  • Figure 5-8: Olaparib - Average Price Analysis for Breast & Ovarian Cancer Treatment (US$), 2018
  • Figure 5-9: Olaparib - Ovarian Cancer Maintenance Therapy Cost Analysis for Reoccurent BRCA Mutated Population (US$), 2018
  • Figure 5-10: Olaparib - Total Cost Analysis for Ovarian Cancer Maintenance Therapy for Reoccurent BRCA Mutated Population (US$), 2018
  • Figure 5-11: Olaparib - Ovarian Cancer Maintenance Therapy Cost Analysis for Platinum Sensitive Germline BRCA Mutated Cancer Population (US$), 2018
  • Figure 5-12: Rucaparib - Available Concentrations of Drug (mg)
  • Figure 5-13: Rucaparib - Dosage Analysis (mg/Day), 2018
  • Figure 5-14: Rucaparib - 300mg & 200mg Tablet Dosage Analysis (mg/12 hour) By Tablet Concentration
  • Figure 5-15: Rucaparib - Price Analysis (US$), 2018
  • Figure 5-16: Rucaparib - Average Price Analysis for Reoccurent BRCA Mutated Cancer Treatment (US$), 2018
  • Figure 5-17: Rucaparib - Ovarian Cancer Maintenance Therapy Cost Analysis for Reoccurent BRCA Mutated Population (US$), 2018
  • Figure 5-18: Rucaparib - Total Cost Analysis for Maintenance Therapy for Reoccurent BRCA Mutated Cancer Population (US$), 2018
  • Figure 5-19: Niraparib - Dosage Analysis (mg/Day)
  • Figure 5-20: Niraparib - Price Analysis (US$), 2018
  • Figure 5-21: Niraparib - Average Price Analysis for Breast & Ovarian Cancer Treatment (US$), 2018
  • Figure 5-22: Niraparib - Maintenance Therapy Cost Analysis for Germline BRCA Mutated Cancer Population (US$), 2018
  • Figure 5-23: Niraparib - Maintenance Therapy Cost Analysis for Non - Germline BRCA Mutated Cancer Population (US$), 2018
  • Figure 5-24: Niraparib - Complete Cancer Treatment Cost Analysis
  • Figure 5-25: Talazoparib - Upcoming Concentration (mg), 2018
  • Figure 5-26: Talazoparib - Expected Price Analysis by Concentration (US$), 2018
  • Figure 5-27: Veliparib - Treatment Course Analysis indicated in Clinical Trials
  • Figure 5-28: Veliparib - Dosage Analysis indicated in Clinical Trials (mg)
  • Figure 5-29: Overall Survival in Patients with Breast Cancer Treated with Carboplatin + Paclitaxel with Veliparib v/s without Veliparib (Months)
  • Figure 6-1: Global - Lynparza (Olaparib) Patent Approval & Expiration Year by Drug Form, 2018
  • Figure 6-2: Lynparza (Olaparib) - Number of Granted Patents & Applications, 2018
  • Figure 6-3: US - Lynparza (Olaparib) Patent Analysis by Number, 2018
  • Figure 6-4: Global - Lynparza (Olaparib) Patent Analysis by Approved Drug Formulations, 2018
  • Figure 6-5: Global - Rubraca (Rucaparib) Patent Aprroval & Expiration Year, 2018
  • Figure 6-6: Rucaparib (Rubraca) - Number of Granted Patents & Applications, 2018
  • Figure 6-7: Global - Zejula (Niraparib) Patent Approval & Expiration Year, 2018
  • Figure 6-8: Zejula (Niraparib) - Granted Patents & Applications, 2018
  • Figure 6-9: Global - Lynparza (Olaparib) Sales (US$ Million), 2015-2017
  • Figure 6-10: Global - Rubraca (Rucaparib) Sales (US$ Milion), 2017
  • Figure 6-11: Global - Zejula (Niraparib) Sales (US$ Million), Q1'2017 & Q2'2017
  • Figure 6-12: Global - PARP Inhibitors End Users (Number of Patients/Year), 2018
  • Figure 7-1: Tolerable Dosage of Rucaparib & Temozolomide Combination Therapy in Clinical Trials for Advanced Malignancy (mg/m2)
  • Figure 7-2: Study of Veliparib + Temozolomide Showing Improved Survival of Patients with Metastatic Melanoma (Months)
  • Figure 7-3: Estimated Glioblastoma Treatment Cost for Temozolomide + PARP Inhibitor Therapy, (US$/Cycle)
  • Figure 7-4: Olaprib & Paclitaxel Combination Therapy Dosage Analysis for Metastatic Gastric Cancer (mg/Day & mg/m2/Day)
  • Figure 7-5: Olaprib & Paclitaxel Combination Therapy Dosage Analysis for Metastatic Gastric Cancer (Administeration/Cycle)
  • Figure 7-6: Olaparib & Paclitaxel Combination Therapy Cost Analysis for Metastatic Gastric Cancer (US$/Cycle)
  • Figure 7-7: Overall Survival of Patients with Metastatic Gastic Cancer with Paclitaxel Chemotherapy vs Combination Therapy with Olaparib (Months)
  • Figure 7-8: Overall Survival in Patients with Triple-Negative Breast Cancer Treated with Gemiciabine & Carboplatin Chemotherapy vs Combination Therapy with Iniparib (Months)
  • Figure 8-1: Overall Progression Free Survival in Patients with Recurrent Platinum-Sensitive High-Grade Serous or Endometrioid Ovarian Cancer Treated with Cediranib + Olaparib v/s Olaparib Monotherapy (Months), 2018
  • Figure 8-2: Olaparib & Cediranib Combination Therapy Dosage Analysis as per Clinical Trials (mg/Day)
  • Figure 9-1: Expected Approval of PARP Inhibitors in the Nearby Future
  • Figure 11-1: US - PARP Inhibitor Market Opprtunity in Ovarian Cancer by Patient Base Undergoing Treatment
  • Figure 11-2: US - PARP Inhibitor Market Opprtunity in Breast Cancer by Patient Base Undergoing Treatment

List of Tables

  • Table 11-1: Ongoing Clinical Trials of PARP Inhibitor Combination Therapy for Prostate Cancer
Back to Top
전화 문의
F A Q